AtaiBeckley (ATAI) FCF Margin (2021 - 2026)
AtaiBeckley (ATAI) posted quarterly FCF Margin of 2210.69% for Q1 2026, down 104613.0% year-over-year from N/an in Q1 2025, and down 89.83% quarter-over-quarter from 1164.57% in Q1 2025.
AtaiBeckley (ATAI) FCF Margin (2021 - 2026) Analysis & Trends
AtaiBeckley has reported FCF Margin for 5 years, with the latest figure at 3158.48% in Q3 2025.
- Quarterly FCF Margin rose 4520902.0% year-over-year to 3158.48% in Q3 2025, while the trailing twelve-month figure through Sep 2025 was 2645.21% (up 2158138.0% YoY) and the FY2024 annual result came in at 26767.21%, up 12738.0% from the prior year.
- FCF Margin for Q1 2026 stood at 2210.69%, down from 1164.57% in the prior quarter.
- The five-year high for FCF Margin was 1164.57% in Q1 2025, with the low at 2210.69% in Q1 2026.
- A 5-year average of 44342.07% and a median of 13069.88% in 2022 frame the typical range for FCF Margin.
- The sharpest annual moves came in 2022 and 2023: FCF Margin plunged 10816967 bps in 2022, then surged 9766092 bps in 2023.
- Over 5 years, FCF Margin stood at 8873.48% in 2021, then tumbled by 809 bps to 80650.0% in 2022, then sank by 52 bps to 122455.56% in 2023, then sank by 65 bps to 202458.33% in 2024, then jumped by 98 bps to 3158.48% in 2025.
- According to Business Quant data, FCF Margin over the past three periods registered 3158.48%, 1977.89%, and 1164.57% for Q3 2025, Q2 2025, and Q1 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 30.39% |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 13.35% |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | - |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 25.68% |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -77,594.17% |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 70.82% |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 22.62% |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -22.35% |
| 10 | AtaiBeckley | 2.69 Bn | 2.69 Bn | - | -3,158.48% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -2,070.01% |
| Mar 31, 2026 | -2,210.69% |
| Sep 30, 2025 | -3,158.48% |
| Jun 30, 2025 | -1,977.89% |
| Mar 31, 2025 | -1,164.57% |
| Mar 31, 2025 | -1,164.57% |
| Dec 31, 2024 | -202,458.33% |
| Sep 30, 2024 | -48,367.50% |
| Jun 30, 2024 | -5,944.32% |
| Dec 31, 2023 | -122,455.56% |
| Sep 30, 2023 | -21,105.75% |
| Jun 30, 2023 | -13,170.93% |
| Mar 31, 2023 | -57,813.51% |
| Dec 31, 2022 | -80,650.00% |
| Sep 30, 2022 | -118,766.67% |
| Jun 30, 2022 | -12,968.82% |
| Dec 31, 2021 | -8,873.48% |
| Sep 30, 2021 | -10,596.99% |
| Mar 31, 2021 | -0.38% |